symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ATNF,0.512,0.600069,327276,3064069,0,0.5003-11.92,-0.0088,180 Life Sciences Corp.,USD,0001690080,US68236V1044,68236V104,NASDAQ Capital Market,NASDAQ,Biotechnology,https://180lifesciences.com,"1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.","Dr. James N. Woody M.D., Ph.D.",Healthcare,US,5,650 507 0669,Building 4,Palo Alto,CA,94306,,0,https://financialmodelingprep.com/image-stock/ATNF.png,2017-06-27,False,False,True,False,False
